Our Pipeline

VB-201

 

Our lead compound, VB-201, has significant potential as a specific, targeted oral disease modifying agent for the control of chronic inflammatory disorders via highly selective modulation of innate immunity including psoriasis, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease and multiple sclerosis. 

Our lead compound, VB-201, has significant potential as a specific, targeted oral disease modifying agent for the control of chronic inflammatory disorders via highly selective modulation of innate immunity including psoriasis, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease and multiple sclerosis. 

 

VB-201 has a mechanism of action that works in a targeted, localized way to modulate the immune system, potentially resulting in better patient outcomes with fewer side effects.  The compound is a first-in-class, orally available drug that shows promise as a long-term treatment for chronic inflammatory diseases and is positioned to work as a standalone or as part of combination therapy.

  • Preclinical Insights – In extensive preclinical studies, VB-201 demonstrated efficacy in multiple immune-inflammatory conditions, including psoriasis. VB-201 showed a unique disease-modifying mechanism for attenuating cell-mediated, pro-inflammatory processes. The favorable safety and efficacy profile observed in preclinical model paved the way for a U.S. investigational new drug (IND) application and Phase 1 clinical trials.
  • Phase 1 Clinical Trials Complete – VB-201 successfully completed four Phase 1 clinical trials involving 120 healthy volunteers under a U.S. IND. These trials included single and multiple-dose studies in which safety and tolerability were similar to placebo.
  • Phase 2 Clinical Trials – We recently completed dosing of our lead compound, VB-201, in Phase 2 clinical trials evaluating treatment in psoriasis and inflammation in atherosclerosis. A double-blind, randomized, dose-ranging, placebo-controlled study was designed to enroll approximately 180 patients with moderate to severe psoriasis. Patients received VB-201 or placebo once-daily for 12 weeks. The primary endpoint of the study is improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12. The study is also evaluating the impact of VB-201 on atherosclerosis in a subset of patients. The study is being conducted at multiple centers in the U.S., Germany and Israel and we expect to announce results in the first half of 2012. 

 

Detailed information on these clinical trials can be found at www.clinicaltrials.gov.